Tucci A - Search Results

1

Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab.

Cattaneo C, Cancelli V, Imberti L, Dobbs K, Sottini A, Pagani C, Belotti A, Re A, Anastasia A, Quaresima V, Tucci A, Chiorini JA, Su HC, Cohen JI, Burbelo PD, Rossi G, Notarangelo LD. Cattaneo C, et al. Among authors: tucci a. Blood Cancer J. 2021 Sep 14;11(9):151. doi: 10.1038/s41408-021-00546-9. Blood Cancer J. 2021. PMID: 34521813 Free PMC article.

2

Transformation of a MGUS to overt multiple myeloma: the possible role of a pituitary macroadenoma secreting high levels of insulin-like growth factor 1 (IGF-1).

Tucci A, Bonadonna S, Cattaneo C, Ungari M, Giustina A, Guiseppe R. Tucci A, et al. Leuk Lymphoma. 2003 Mar;44(3):543-5. doi: 10.1080/1042819021000037895. Leuk Lymphoma. 2003. PMID: 12688330

3

Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments.

Cattaneo C, Spedini P, Casari S, Re A, Tucci A, Borlenghi E, Ungari M, Ruggeri G, Rossi G. Cattaneo C, et al. Among authors: tucci a. Leuk Lymphoma. 2006 Jun;47(6):1013-7. doi: 10.1080/10428190500473113. Leuk Lymphoma. 2006. PMID: 16840190

4

A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy.

Tucci A, Ferrari S, Bottelli C, Borlenghi E, Drera M, Rossi G. Tucci A, et al. Cancer. 2009 Oct 1;115(19):4547-53. doi: 10.1002/cncr.24490. Cancer. 2009. PMID: 19562776 Free article.

5

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.

Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U; Fondazione Italiana Linfomi. Ladetto M, et al. Blood. 2013 Nov 28;122(23):3759-66. doi: 10.1182/blood-2013-06-507319. Epub 2013 Oct 1. Blood. 2013. PMID: 24085766 Free article. Clinical Trial.

6

The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi.

Rossi G, Marcheselli L, Dondi A, Bottelli C, Tucci A, Luminari S, Arcaini L, Merli M, Pulsoni A, Boccomini C, Puccini B, Micheletti M, Martinelli G, Rossi A, Zilioli VR, Bozzoli V, Balzarotti M, Bolis S, Cabras MG, Federico M. Rossi G, et al. Among authors: tucci a. Am J Hematol. 2015 Jan;90(1):56-61. doi: 10.1002/ajh.23872. Epub 2014 Nov 19. Am J Hematol. 2015. PMID: 25327841 Free article.

7

Peri-operative complications and hematologic improvement after first-line splenectomy for splenic marginal zone lymphoma.

Pata G, Damiani E, Bartoli M, Solari S, Anastasia A, Pagani C, Tucci A, Ragni F. Pata G, et al. Among authors: tucci a. Leuk Lymphoma. 2016;57(6):1467-70. doi: 10.3109/10428194.2015.1092529. Epub 2015 Oct 15. Leuk Lymphoma. 2016. PMID: 26373930 No abstract available.

8

Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines.

Pedretti S, Urpis M, Leali C, Borghetti P, Baushi L, Sala R, Tucci A, Greco D, Pasinetti N, Triggiani L, Rossi G, Calzavara-Pinton P, Magrini SM, Buglione M. Pedretti S, et al. Among authors: tucci a. Tumori. 2018 Oct;104(5):394-400. doi: 10.5301/tj.5000606. Epub 2018 May 8. Tumori. 2018. PMID: 28218382

9

Still a role for surgery as first-line therapy of splenic marginal zone lymphoma? Results of a prospective observational study.

Pata G, Bartoli M, Damiani E, Solari S, Anastasia A, Pagani C, Tucci A. Pata G, et al. Among authors: tucci a. Int J Surg. 2017 May;41:143-149. doi: 10.1016/j.ijsu.2017.03.077. Epub 2017 Mar 30. Int J Surg. 2017. PMID: 28366762 Free article.

10

slan⁺ Monocytes and Macrophages Mediate CD20-Dependent B-cell Lymphoma Elimination via ADCC and ADCP.

Vermi W, Micheletti A, Finotti G, Tecchio C, Calzetti F, Costa S, Bugatti M, Calza S, Agostinelli C, Pileri S, Balzarini P, Tucci A, Rossi G, Furlani L, Todeschini G, Zamò A, Facchetti F, Lorenzi L, Lonardi S, Cassatella MA. Vermi W, et al. Among authors: tucci a. Cancer Res. 2018 Jul 1;78(13):3544-3559. doi: 10.1158/0008-5472.CAN-17-2344. Epub 2018 May 10. Cancer Res. 2018. PMID: 29748373

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

481 results

Search Page

Filters